Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.1062567928746 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern’s scoring:
- New report examines the Global general anesthesia drugs market trends & industry forecast by 2017 – 2025 (whatech.com)
- AndroGel Maker Hit with $150 Million in Punitive Damages at Trial (injurylawyer-news.com)
- AbbVie pill combo Mavyret gets FDA OK for all forms of hepatitis C (chicago.suntimes.com)
- Artemis Investment Management LLP Adjusts Its Stake in AbbVie Inc. (ABBV) – Modern Readers (modernreaders.com)
- Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data (finance.yahoo.com)
Several equities research analysts have recently weighed in on the company. BidaskClub lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Piper Jaffray Companies reissued a “buy” rating and set a $85.00 target price on shares of AbbVie in a research report on Thursday, August 3rd. Cowen and Company set a $70.00 target price on AbbVie and gave the stock a “hold” rating in a research report on Sunday, July 30th. Vetr raised AbbVie from a “hold” rating to a “buy” rating and set a $76.28 target price on the stock in a research report on Wednesday, July 26th. Finally, Credit Suisse Group reissued a “neutral” rating and set a $74.00 target price (up previously from $65.00) on shares of AbbVie in a research report on Thursday, July 20th. Nine equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $74.66.
Shares of AbbVie (NYSE ABBV) traded up 0.77% on Wednesday, hitting $72.02. The company’s stock had a trading volume of 4,536,324 shares. The company has a 50 day moving average of $72.12 and a 200 day moving average of $66.41. AbbVie has a 1-year low of $55.06 and a 1-year high of $75.04. The firm has a market cap of $114.62 billion, a PE ratio of 17.71 and a beta of 1.50. AbbVie also was the target of unusually large options trading on Monday. Investors acquired 278 put options on the company. This represents an increase of 121% compared to the typical daily volume of 126 put options.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.02. The business had revenue of $6.94 billion for the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 154.76% and a net margin of 24.77%. The business’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 EPS. Equities analysts forecast that AbbVie will post $5.52 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 3.55%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s dividend payout ratio (DPR) is 62.90%.
In related news, Chairman Richard A. Gonzalez sold 193,131 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the completion of the transaction, the chairman now directly owns 469,623 shares of the company’s stock, valued at approximately $33,343,233. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Richard A. Gonzalez sold 65,861 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total value of $4,676,131.00. Following the completion of the transaction, the chief executive officer now directly owns 342,353 shares of the company’s stock, valued at $24,307,063. The disclosure for this sale can be found here. Insiders sold a total of 600,026 shares of company stock valued at $41,852,724 over the last three months. Corporate insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AbbVie (ABBV) Earns Daily Coverage Optimism Rating of 0.17” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/08/09/abbvie-abbv-earns-daily-coverage-optimism-rating-of-0-17.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.